Search | IOVS | ARVO Journals

View

Showing 1 – 6 of 6

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract September 2016

No improvement in visual outcome over time in two cohorts from the same county in patients treated for wet AMD.

Marion Schroeder; Lena Rung; Monica K Lovestam Adrian

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):3359. doi:

ARVO Annual Meeting Abstract March 2012

Early Neural Changes In Newly Onset Type 2 Diabetes Is Measurable With Electrophysiology But Not With OCT

Maria Tyrberg; Monica K. Lovestam Adrian; Vesna Ponjavic; Sten Andreasson

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):2873. doi:

ARVO Annual Meeting Abstract March 2012

Despite Detoriation In Visual Acuity, Patients Treated With Ranibizumab For Wet, Age-related Macular Degeneration Did Not Demonstrate Any Raise In Worrying Related Quality Of Life Related Items

Lena Rung, II; Monica K. Lovestam Adrian

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):4429. doi:

ARVO Annual Meeting Abstract April 2010

Both Age and Diabetes Duration Influence the Mferg Response in Diabetic Eyes with No or Minimal Retinopathy

M. K. Lovestam Adrian; J. Larsson, II; K. Holm, III

Invest. Ophthalmol. Vis. Sci.. 2010; 51(13):4232. doi:

ARVO Annual Meeting Abstract April 2009

In Diabetic Eyes, the Mferg Amplitudes Are Lower in the Nasal Foveal Area Compared to the Temporal Area

M. K. Lovestam Adrian; K. Holm, II; S. Andreasson, III

Invest. Ophthalmol. Vis. Sci.. 2009; 50(13):1323. doi:

ARVO Annual Meeting Abstract May 2007

Patients With Diabetic Retinopathy and Neuropathy Showed Lower Amplitudes on the Multifocal Vep Than Diabetic Patients With the Same Level of Retinopathy but No Neuropathy

M. K. Lovestam Adrian; L. Gränse; G. Andersson; S. Andreasson

Invest. Ophthalmol. Vis. Sci.. 2007; 48(13):5010. doi:

Advertisement